Advanced Renal Cell Carcinoma (DBCOND0032596)

Identifiers

Synonyms

Advanced Renal Cell Cancer / Advanced Renal Cell Carcinoma (aRCC) / Advanced Renal Cell Carcinoma (RCC) / Advanced renal cell carcinoma / Adenocarcinoma of kidney / Renal cell cancer / Renal cell carcinoma stage unspecified / Grawitz tumor / Renal cell carcinoma NOS / Renal cell adenocarcinoma / Grawitz tumour / Renal cell carcinoma (disorder) / Renal cell carcinoma / Renal cell carcinoma (morphologic abnormality) / Carcinoma, Renal Cell / Clear cell carcinoma of kidney (disorder)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Avelumab	An anti-PD-L1 monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.	Programmed cell death 1 ligand 1target
Axitinib	An oral VEGFR and kinase inhibitor used for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy.	Vascular endothelial growth factor receptor 1target Vascular endothelial growth factor receptor 2target Vascular endothelial growth factor receptor 3target Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme Cytochrome P450 1A2enzyme Cytochrome P450 2C19enzyme UDP-glucuronosyltransferase 1A1enzyme ATP-dependent translocase ABCB1transporter Solute carrier organic anion transporter family member 1B1transporter Tyrosine-protein kinase ABL1target
Belzutifan	An inhibitor of hypoxia-inducible factor 2α used as an antineoplastic in the treatment of certain cancers associated with von Hippel-Lindau (VHL) disease.	Endothelial PAS domain-containing protein 1target UDP-glucuronosyltransferase 2B17enzyme Cytochrome P450 2C19enzyme Cytochrome P450 3A4enzyme ATP-dependent translocase ABCB1transporter Solute carrier organic anion transporter family member 1B1transporter Solute carrier organic anion transporter family member 1B3transporter Multidrug and toxin extrusion protein 2transporter
Cabozantinib	A tyrosine kinase inhibitor used to treat advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer.	Cytochrome P450 3A4enzyme Cytochrome P450 2C9enzyme Hepatocyte growth factor receptortarget Vascular endothelial growth factor receptor 2target Proto-oncogene tyrosine-protein kinase receptor Rettarget Cytochrome P450 2C8enzyme
Lenvatinib	A receptor tyrosine kinase inhibitor used for the treatment of metastatic thyroid cancer, advanced renal cell carcinoma in combination with everolimus, and unresectable hepatocellular carcinoma.	Vascular endothelial growth factor receptor 1target Vascular endothelial growth factor receptor 2target Vascular endothelial growth factor receptor 3target Fibroblast growth factor receptor 1target Fibroblast growth factor receptor 2target Fibroblast growth factor receptor 3target Fibroblast growth factor receptor 4target Platelet-derived growth factor receptor alphatarget Proto-oncogene tyrosine-protein kinase receptor Rettarget Mast/stem cell growth factor receptor Kittarget ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Cytochrome P450 3A4enzyme Aldehyde oxidaseenzyme Cytochrome P450 2C8enzyme Cytochrome P450 2C9enzyme Cytochrome P450 1A2enzyme Cytochrome P450 2B6enzyme Cytochrome P450 2C19enzyme Solute carrier family 22 member 6transporter Organic anion transporter 3transporter Solute carrier family 22 member 2transporter Solute carrier organic anion transporter family member 1B1transporter Bile salt export pumptransporter Cytochrome P450 2D6enzyme Solute carrier organic anion transporter family member 1B3transporter
Nivolumab	A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.	Programmed cell death protein 1target Programmed cell death 1 ligand 1target
Pazopanib	An antineoplastic agent used in the treatment of advanced renal cell cancer and advanced soft tissue sarcoma in patients with prior chemotherapy.	Vascular endothelial growth factor receptor 1target Vascular endothelial growth factor receptor 2target Vascular endothelial growth factor receptor 3target Platelet-derived growth factor receptor alphatarget Platelet-derived growth factor receptor betatarget Mast/stem cell growth factor receptor Kittarget Cytochrome P450 3A4enzyme Cytochrome P450 2D6enzyme Cytochrome P450 2C8enzyme Cytochrome P450 1A2enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Solute carrier organic anion transporter family member 1B1transporter UDP-glucuronosyltransferase 1A1transporter Fibroblast growth factor receptor 3target Tyrosine-protein kinase ITK/TSKtarget Fibroblast growth factor 1target SH2B adapter protein 3target
Pembrolizumab	A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.	Programmed cell death protein 1target Programmed cell death 1 ligand 1target
Sorafenib	A kinase inhibitor used to treat unresectable liver carcinoma, advanced renal carcinoma, and differentiated thyroid carcinoma.	Serine/threonine-protein kinase B-raftarget Receptor-type tyrosine-protein kinase FLT3target RAF proto-oncogene serine/threonine-protein kinasetarget Vascular endothelial growth factor receptor 3target Platelet-derived growth factor receptor betatarget Mast/stem cell growth factor receptor Kittarget Vascular endothelial growth factor receptor 2target Cytochrome P450 3A4enzyme UDP-glucuronosyltransferase 1A9enzyme Cytochrome P450 2B6enzyme Cytochrome P450 2C8enzyme Cytochrome P450 3A5enzyme Cytochrome P450 3A7enzyme Cytochrome P450 2C9enzyme ATP-binding cassette sub-family C member 4transporter ATP-dependent translocase ABCB1transporter ATP-binding cassette sub-family C member 2transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Cytochrome P450 1A2enzyme Cytochrome P450 2C19enzyme Cytochrome P450 2D6enzyme UDP-glucuronosyltransferase 1A1enzyme RalA-binding protein 1transporter Fibroblast growth factor receptor 1target Proto-oncogene tyrosine-protein kinase receptor Rettarget Vascular endothelial growth factor receptor 1target Solute carrier organic anion transporter family member 1B1transporter Epidermal growth factor receptortarget
Temsirolimus	A antineoplastic agent used in the treatment of renal cell carcinoma (RCC) that works by inhibiting mTOR.	Serine/threonine-protein kinase mTORtarget Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme Cytochrome P450 3A7enzyme Cytochrome P450 2D6enzyme ATP-dependent translocase ABCB1transporter
Tivozanib	A kinase inhibitor to treat adult patients with renal cell carcinoma (RCC) who have failed prior systemic therapies or experienced relapsed disease.	Cytochrome P450 3A4enzyme Albumincarrier Vascular endothelial growth factor receptor 1target Vascular endothelial growth factor receptor 2target Vascular endothelial growth factor receptor 3target Mast/stem cell growth factor receptor Kittarget Platelet-derived growth factor receptor betatarget ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Receptor-type tyrosine-protein kinase FLT3target Platelet-derived growth factor receptor alphatarget Protein-tyrosine kinase 6target Angiopoietin-1 receptortarget Fibroblast growth factor receptor 1target Hepatocyte growth factor receptortarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT02429440	Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides	Incomplete Freund's adjuvant	treatment	1 / 2	unknown_status
NCT04957160	Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination	No drug interventions	Not Available	Not Available	completed
NCT06345183	Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients	Ipilimumab Lenvatinib Nivolumab Pembrolizumab	Not Available	Not Available	active_not_recruiting
NCT05928806	Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial	Balstilimab Botensilimab Ipilimumab Nivolumab	treatment	2	recruiting
NCT04071223	Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study	Cabozantinib	treatment	2	recruiting
NCT04514484	Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	Cabozantinib Nivolumab	treatment	1	active_not_recruiting
NCT04522323	A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma	Axitinib Lenvatinib Volrustomig	treatment	1	recruiting
NCT03647878	Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.	No drug interventions	Not Available	Not Available	recruiting
NCT05092373	Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax	Albumin human Atezolizumab Cabozantinib Paclitaxel	treatment	1	recruiting
NCT05361434	A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults	No drug interventions	Not Available	Not Available	active_not_recruiting
NCT05703854	Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma	Cyclophosphamide Fludarabine Natural Killer Cell	treatment	1 / 2	recruiting
NCT05239533	Study of Nivolumab in Combination with 177Lu-girentuximab for Kidney Cancer	Girentuximab Lutetium Lu-177 Nivolumab	treatment	2	recruiting
NCT05641545	IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients	No drug interventions	other	1	terminated
NCT01513187	Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma	Interferon alfa Pazopanib	treatment	1 / 2	completed
NCT05967533	The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors	No drug interventions	treatment	1	recruiting
NCT00771147	A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ®	Sorafenib	Not Available	Not Available	completed
NCT01030783	A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma	Sorafenib Tivozanib	treatment	3	completed
NCT03696407	A Non-interventional Retrospective Study to Describe Early Clinical Experience With Cabozantinib in Patients With Advanced Renal Cell Carcinoma (RCC) in the UK	No drug interventions	Not Available	Not Available	completed
NCT03117309	Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma	Ipilimumab Nivolumab	treatment	2	active_not_recruiting
NCT02735252	PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer	No drug interventions	basic_science	Not Available	active_not_recruiting
NCT01727336	Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma	Axitinib Dalantercept	treatment	2	terminated
NCT05262413	A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC)	Lenvatinib QL1706	treatment	1 / 2	unknown_status
NCT00422019	A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma	Dihydrotachysterol Rilotumumab	treatment	2	completed
NCT05119335	A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma	No drug interventions	treatment	1 / 2	recruiting
NCT01381822	Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors	Evofosfamide	treatment	1	unknown_status
NCT04941365	Quantifying Systemic Immunosuppression to Personalize Cancer Therapy	No drug interventions	diagnostic	Not Available	withdrawn
NCT05522231	Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)	Axitinib Everolimus Fruquintinib Sintilimab	treatment	2 / 3	recruiting
NCT00494091	Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma	Temsirolimus	treatment	2	completed
NCT04902040	Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies	Atezolizumab Avelumab Durvalumab Nivolumab Pembrolizumab Plinabulin	treatment	1 / 2	recruiting
NCT04203901	Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma	Everolimus Ipilimumab Lenvatinib Nivolumab	treatment	2	terminated
NCT01582672	Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma	Rocapuldencel-T Sunitinib	treatment	3	terminated
NCT01076010	An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).	Sorafenib Tivozanib	treatment	3	completed
NCT02156895	Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea	Axitinib	Not Available	Not Available	completed
NCT06127238	Study of ST-1898 in Advanced Renal Cell Carcinoma	No drug interventions	treatment	1 / 2	recruiting
NCT00486538	Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib	Linifanib	treatment	2	completed
NCT05444933	A Study to Collect Pre-existing Data on the Administration of Cabozantinib in Participants With Advanced Renal Cell Carcinoma (aRCC) Who Initiated Cabozantinib in 2nd Line in a Real-life Clinical Setting in France.	No drug interventions	Not Available	Not Available	completed
NCT03229083	Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma	No drug interventions	supportive_care	Not Available	recruiting
NCT03829111	CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer	Bifidobacterium longum Ipilimumab Lactobacillus acidophilus Nivolumab	treatment	1	completed
NCT05394493	An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK	Avelumab Axitinib	Not Available	Not Available	completed
NCT06265285	Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program	Nivolumab	health_services_research	2	recruiting
NCT05135832	Patient Reported Outcomes by Patients With Metastatic Renal Cell Carcinoma	No drug interventions	supportive_care	Not Available	unknown_status
NCT02231749	Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)	Ipilimumab Nivolumab Sunitinib	treatment	3	active_not_recruiting
NCT06399419	CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer	Ipilimumab Nivolumab	treatment	1	recruiting
NCT03339219	A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma	Cabozantinib	treatment	2	completed
NCT03200717	Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment	Pazopanib	treatment	2	completed
NCT03428217	CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma	Cabozantinib Telaglenastat	treatment	2	completed
NCT00700258	Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]	Axitinib Sunitinib Temsirolimus	Not Available	Not Available	completed
NCT00425035	Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2	Panitumumab	treatment	2	completed
NCT00467025	AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib	Sorafenib Trebananib	treatment	2	completed
NCT05935748	Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)	Palbociclib	treatment	2	recruiting
NCT03707574	Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study	No drug interventions	Not Available	Not Available	active_not_recruiting
NCT05868174	Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors	Girentuximab Lutetium Lu-177	treatment	1	recruiting
NCT00895674	Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar	Sorafenib	Not Available	Not Available	completed
NCT01664182	Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer	Bevacizumab Pazopanib Sorafenib Sunitinib Trebananib	treatment	2	completed
NCT00197860	Dendritic Cell Based Therapy of Renal Cell Carcinoma	No drug interventions	treatment	1 / 2	completed
NCT02143492	Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC	No drug interventions	Not Available	Not Available	completed
NCT00425204	Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment	Panitumumab	treatment	2	completed
NCT00853372	AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib	Sunitinib Trebananib	treatment	2	completed
NCT05122546	CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer	Bifidobacterium longum Cabozantinib Lactobacillus acidophilus Nivolumab	treatment	1	active_not_recruiting
NCT05759923	First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours	No drug interventions	treatment	1	recruiting